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A B S T R A C T
Objectives
This is a protocol for a Cochrane Review (intervention). The objectives are as follows:
To assess the comparative eCicacy of optical, pharmacological and environmental interventions for slowing myopia progression in children
using network meta-analysis.
To generate a relative ranking of the interventions for myopia control according to their eCicacy.
To produce a brief economic commentary, summarising the economic evaluations assessing interventions for myopia control in children.
To maintain the currency of the evidence using a living systematic review approach.
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B A C K G R O U N D
Description of the condition
Myopia (or nearsightedness) is a common refractive anomaly of
the eye that occurs when parallel rays of light are brought to a
focus in front of the retina with accommodation at rest, causing
distant objects to appear blurred and near objects to remain clear
(Morgan 2012). Myopia most oHen results from the eyeball being
too long (axial elongation), but can also occur when the image-
forming structures of the eye are too strong (FlitcroH 2019).
The prevalence of myopia shows significant age, ethnic and
regional variation (Rudnicka 2016). Currently, 30% to 50% of adults
in the USA and Europe are myopic (Dolgin 2015). Myopia is already
reaching "epidemic" proportions in children and young adults
in urban areas of East and South East Asia, with over 80% of
children being myopic by the time they complete their high school
education (Dolgin 2015). If current trends continue, it is estimated
that by 2050 there will be approximately 5 billion (5000 million)
people with myopia (50% of the world's population), with around
10% having high myopia (defined as a spherical equivalent of -5
dioptres (D) or worse) (Holden 2016).
The aetiology of myopia involves a complex interaction between
environmental and genetic factors. Although genetic inheritance
is a well-established predisposing factor for myopia, genetic
factors cannot explain the rapidly rising prevalence of the
condition (Williams 2019). A recent Mendelian randomisation
study using the UK Biobank cohort, provided strong evidence
for the cumulative eCect of additional years in education on
myopia development (Mountjoy 2018). Mendelian randomisation
is a statistical approach that uses genetics to provide information
about the relationship between an exposure and outcome. This
study estimated that for each additional year in education,
myopic spherical equivalent increased by -0.27 D. Evidence from
a number of observational studies further supports the causal
association between environmental and social factors and myopia
development (Morgan 2018).
Epidemiological studies have shown that myopia is an established
risk factor for a number of ocular pathologies, including cataract,
glaucoma and retinal detachment (FlitcroH 2012). Although
myopia-related complications can occur irrespective of  age and
degree of myopia (Dhakal 2018), the excessive axial elongation
associated with higher degrees of myopia causes biomechanical
stretching of the outer coat of the eye, increasing the risk of
sight-threatening pathologies such as posterior staphyloma and
myopic maculopathy (Saw 2005; Verkicharla 2015). A meta-analysis
of population studies reporting blindness and visual impairment
due to myopic maculopathy (Fricke 2018), estimated that in
2015, approximately 10 million people had visual impairment
due to myopic macular degeneration, of whom 3 million were
blind. Although the sight-threatening pathologies associated with
myopia usually occur later in life, the underlying myopia develops
during childhood and therefore interventions to reduce the
progression of myopia have the potential to reduce future visual
impairment.
Description of the intervention
Most cases of myopia develop during childhood and the prevalence
of myopia begins to increase noticeably aHer the age of six years
(McCullough 2016). Progression rates vary significantly, with rates
in Asian children being approximately 0.20 D per year faster than
their age-matched European counterparts (Donovan 2012). Since
myopia tends to stabilise in late adolescence, interventions to slow
myopia progression need to be delivered in childhood.
Interventions to slow progression of myopia can be grouped
into three broad categories: optical, pharmacological and
environmental (Wildsoet 2019). Optical interventions include a
variety of spectacle and contact lens designs. Spectacles are the
least invasive and most accessible method for potentially slowing
myopia. Spectacle options include refractive under-correction,
customised spectacle lenses, as well as bifocal and progressive
addition designs. SoH multifocal and approved myopia control
contact lenses are increasingly being used for myopia management
in children (Efron 2020). Centre-distance soH multifocal lens
designs incorporate a central zone that contains the distance
correction with peripheral regions of the lens containing increased
positive power (myopic defocus). This is achieved by either
a gradual increase in power towards the periphery or using
concentric peripheral zones of alternating myopic defocus and
distance correction. Orthokeratology (ortho-K) involves the use
of specialised rigid contact lenses that are worn during sleep to
change the topography of the cornea to reduce myopic refractive
error and also manipulate peripheral retinal defocus to slow eye
growth. Safety remains a concern because of the risk of sight-
threatening microbial keratitis and there is also the possibility of
regression or rebound aHer discontinuation of lens wear or change
to an alternative refractive intervention (VanderVeen 2019).
The most commonly used topical pharmacological intervention
for myopia control is the non-selective muscarinic antagonist,
atropine, which has been widely used in clinical trials in
concentrations ranging from 0.01% to 1.0%. Although higher
atropine concentrations have been shown to be eCective in
retarding myopia progression in children, the higher incidence of
side eCects with higher doses, including cycloplegia (inhibition of
accommodation) and pupil dilation (which causes blur for near
vision and photophobia) limits its long-term use. Furthermore, a
rebound eCect aHer discontinuation of therapy is more pronounced
with higher concentrations of atropine (Chia 2014). More recent
studies have evaluated the eCicacy of lower concentrations to
reduce side eCects and lessen the likelihood of rebound. The results
of these studies have led to a renewed interest in the clinical
application of low-dose atropine (e.g. 0.01% and 0.05%) for myopia
control (Wu 2019). Other pharmacological agents that have been
evaluated for myopia control include tropicamide, cyclopentolate,
the selective M1 muscarinic antagonist, pirenzipine, and the oral
adenosine antagonist, 7-Methylxanthine.
Evidence that more time spent on near work activities is associated
with higher odds of developing myopia (Huang 2015), and the
observation that increased time spent outdoors is protective
against myopia, aHer adjusting for near work, parental myopia
and ethnicity (Rose 2008), have raised the possibility that
environmental or behavioural interventions could be eCective for
myopia control. Trials of school-based programs that promote
outdoor activities, conducted in East Asia, have reported a lower
incidence of myopia onset but no significant eCect on progression
following onset of myopia (He 2015; Wu 2018).
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How the intervention might work
Studies in experimental animals have shown that optically-induced
changes to the eCective refractive status of the eye can regulate
eye growth and influence refractive development (Troilo 2019).
Specifically, the observation that imposed relative myopic defocus
(image focused in front of the retina) can slow axial elongation
has been the impetus for the development of novel multifocal
spectacles and contact lenses that provide clear central vision,
whilst at the same time presenting myopic defocus over a large
proportion of the visual field. The critical area ratio required for
these simultaneous competing defocus signals to dominate eye
growth is currently unclear. However, the relative treatment eCects
reported for diCerent optical treatment regimens suggest that there
appears to be an eccentricity-dependent decrease in the eCicacy
of myopic defocus beyond the near periphery (Smith 2014; Smith
2020).
Orthokeratology involves corneal reshaping lenses that are worn
overnight to flatten the central cornea and reduce its dioptric
power. The geometry of these lenses also creates a corneal profile
that produces relative myopic defocus.
The precise mechanism by which anti-muscarinic agents reduce
myopic progression is not fully understood. A non-accommodative
mechanism is thought to be the most likely, and alternative targets
have been proposed, including eye growth regulatory pathways
that arise in the retina and are relayed to the sclera via the retinal
pigment epithelium and choroid (McBrien 2013, Upadhyay 2020).
The protective eCect of increased time outdoors on myopia
development is thought to be related to the higher light intensity
of sunlight and possibly its spectral composition (French 2013).
Light levels have been shown to influence refractive development
in animal models (Smith 2012). Higher light intensities stimulate
retinal dopamine production, which is thought to inhibit axial
elongation (Feldkaemper 2013).
Why it is important to do this review
As a result of its increasing global prevalence and association
with sight-threatening pathologies, myopia is emerging as a major
public health concern. Myopia is predicted to aCect almost half of
the world’s population by 2050, and the pathologic consequences
of high myopia increase the risk of irreversible visual impairment
and blindness. There has been considerable interest in the
development of strategies to delay the onset of myopia and slow
its progression. Myopia control interventions are increasingly being
used in routine clinical practice (Efron 2020; WolCsohn 2016).
Evidence from randomised controlled trials (RCTs) indicates that
the progression of myopia can be slowed by diCerent interventions,
although treatment eCicacy is highly variable.
There is a broad consensus that the primary endpoints for judging
eCicacy in clinical trials of myopia control interventions should
include change in axial length in addition to change in refractive
error (Walline 2018, WolCsohn 2019). Myopia development and
progression usually occur due to axial elongation. Therefore,
axial length may be a better predictor of future progression and
consequent risk of posterior pole complications (Brennan 2020).
In terms of a minimally important diCerence of the key eCicacy
outcomes in myopia control trials, an expert panel concluded that
a mean diCerence between intervention groups of 0.25 D per year
would be regarded as clinically significant (0.75 D over the course
of a three-year study) (Walline 2018). This would correspond to a
change in axial length of approximately 0.1 mm per year.
An updated Cochrane Review, published in January 2020 (Walline
2020), evaluated the eCicacy of a number of interventions,
including spectacles, contact lenses and pharmaceutical agents,
for slowing the progression of myopia in children. This review
concluded that topical anti-muscarinic medication was eCective in
slowing myopia progression. Multifocal lenses, either spectacles or
contact lenses, also conferred a small benefit. Although the update
was published in 2020, the review only included evidence published
up to the end of 2018. Consequently, in this rapidly moving field,
the results of important trials have subsequently been reported.
Eye care professionals oHen find it diCicult to assimilate potentially
conflicting evidence to inform their clinical decision-making
(Douglass 2020). It is therefore important that practitioners
can access high-quality and up-to-date evidence to inform
practice. Moreover, parents of myopic children also need reliable
information to help them to understand and interpret research
findings. Given the large number of diCerent interventions
available for myopia control and the large number of completed
and ongoing RCTs on this topic, there is an urgent need to
evaluate the comparative eCectiveness of diCerent interventions.
A network meta-analysis (NMA) oCers an advantage over a
standard pairwise meta-analysis in that it provides both direct
comparisons of individual trials and indirect comparisons not
directly evaluated in trials across a network of studies, thus
generating the comparativeness of all interventions in a coherent
manner. A NMA can also provide relative rankings of interventions
to inform clinical decision-making.
There are significant resource implications associated with myopia
for both individuals and health care systems. This includes both
corrected and uncorrected myopic refractive error. Lim 2009
estimated the mean direct costs of managing myopia in school-
aged children in Singapore. These costs included optometrist visits,
spectacles, contact lenses and travel costs. The mean cost was
estimated as USD 148 (median SGD 83.33) per year in 2006. In
addition, Zheng 2013 estimated the lifetime costs for a person with
myopia over an 80-year lifespan to be USD 17,020 in 2011. There
are also associated costs and quality of life impacts associated
with uncorrected refractive error. Tahhan 2013 found a significant
reduction in health state utility associated with uncorrected
refractive error. Fricke 2012 estimated that the direct costs of
correcting all cases of uncorrected refractive error globally would
be approximately USD 28 billion (USD 28,000 million; price year
not stated). Given these cost estimates, understanding the current
evidence base for myopia control is key for both individuals and
healthcare decision-makers.
Following publication, we plan to maintain this review as a
living systematic review. This will involve searching the literature
every six months and incorporating new evidence as it becomes
available. This approach is appropriate for this review since
it addresses an important clinical topic and there is currently
significant uncertainty as to the most eCective intervention. It
is therefore important that consumers and healthcare providers
have access to the most up-to-date evidence to make informed
decisions. The review authors are aware of several relevant ongoing
trials that will be important to incorporate in a timely manner.
Interventions for myopia control in children: a living systematic review and network meta-analysis (Protocol)
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O B J E C T I V E S
To assess the comparative eCicacy of optical, pharmacological and
environmental interventions for slowing myopia progression in
children using network meta-analysis.
To generate a relative ranking of the interventions for myopia
control according to their eCicacy.
To produce a brief economic commentary, summarising the
economic evaluations assessing interventions for myopia control
in children.
To maintain the currency of the evidence using a living systematic
review approach.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials of optical,
pharmacological and environmental interventions used alone or in
combination for slowing the progression of myopia in children.
Types of participants
This review will consider studies that included children 18 years
old and younger. We will exclude trials in which the majority of
participants were older than 18 years at the start of the trial. We
will also exclude trials that included participants with spherical
equivalent myopia less than 0.50 D at baseline. The spherical
equivalent is calculated by the sum of the spherical power plus half
the cylindrical power of the refractive error.
We will include all participants who were randomised to the
intervention comparisons of interest and had the relevant
outcomes measured, irrespective of whether the outcomes were
reported.
Types of interventions
We will include trials in which any of the interventions listed below
were compared with a control group, or with each other. For the
purposes of the analysis, we will define a control group as a placebo
intervention or single vision spectacle or contact lenses.
• Undercorrection of myopia
• Bifocal or progressive addition spectacle lenses, single vision
peripheral defocus spectacle lenses
• Concentric bifocal soH contact lenses, multifocal soH contact
lenses, rigid gas permeable contact lenses or corneal reshaping
(orthokeratology) contact lenses
• Atropine (stratified according to dosing regime as high (≥ 0.5%),
moderate (0.1 % to < 0.5%) and low (< 0.1%)
• Other pharmaceutical agents (e.g. pirenzepine, 7-
Methylxanthine)
• Environmental interventions (e.g. time spent outdoors,
modifications to the performance of near work)
Types of outcome measures
Critical outcomes
Progression of myopia
Progression of myopia will be assessed by:
• mean change in refractive error (spherical equivalent in D) from
baseline for each year of follow-up and measured by any method
(e.g. objective or subjective refraction); and
• mean change in axial length for each year of follow-up in
millimetres (mm) and measured by any method (e.g. ultrasound
or optical biometry).
Change in refractive error and axial length following cessation
of treatment
To evaluate rebound when children in the treatment group are
switched to the control treatment and followed for a minimum
period of one year.
Important outcomes
Incidence of adverse events
Quality of life
Measured by any validated vision-related or health-related quality
of life questionnaire (e.g. National Eye Institute (NEI) Visual




We will report outcomes at one year, two years and as available for
the duration of the study. We will impose no restrictions based on
the length of follow-up.
Brief economic commentary
We also plan to present any evidence regarding relevant economic
evaluations, as a brief economic commentary.
Search methods for identification of studies
Electronic searches
The Cochrane Eyes and Vision Information Specialist will search the
following electronic databases for randomised controlled trials and
controlled clinical trials. There will be no restrictions to language
or date of publication. In addition searches will be carried out on
MEDLINE and Embase using economic search filters to specifically
identify economic studies and for adverse eCects information
relevant to this review.
This review will be developed as a living systematic review and the
searches will be re-run on a six monthly basis.
• Cochrane Central Register of Controlled Trials (CENTRAL) (which
contains the Cochrane Eyes and Vision Trials Register) in the
Cochrane Library (latest issue) (Appendix 1).
• MEDLINE Ovid (1946 to present) (Appendix 2).
• MEDLINE Ovid - economic search (1946 to present) (Appendix 3).
• MEDLINE Ovid - adverse events (1946 to present) (Appendix 4).
• Embase Ovid (1980 to present) (Appendix 5).
• Embase Ovid - economic search (1980 to present) (Appendix 6).
• Embase Ovid - adverse events (1980 to present) (Appendix 7).
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• ISRCTN registry (www.isrctn.com/editAdvancedSearch)
(Appendix 8).
• US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (www.clinicaltrials.gov) (Appendix 9).
• World Health Organization (WHO) International Clinical Trials
Registry Platform (ICTRP) (www.who.int/ictrp) (Appendix 10).
Searching other resources
We will search the reference lists of identified trial reports to identify
additional trials. We will also contact the principal investigators
of included trials for details of other potentially relevant trials not
identified by the electronic searches, and of recently completed or
ongoing trials.
Data collection and analysis
Selection of studies
The Information Specialist at Cochrane Eyes and Vision will
download all titles and abstracts retrieved from the electronic
searches to EndNote (www.endnote.com/) and remove duplicates
before uploading to Covidence (Covidence). Two review authors
will independently review the titles and abstracts of the search
results based on the eligibility criteria stated above. Abstracts will
be categorised for inclusion as 'Yes', 'Maybe' or 'No'. We will obtain
the full text of articles for the studies categorised as 'Maybe' and
'Yes', and reassess them for final eligibility. AHer examining the
full text, studies will be labelled as 'include' or 'exclude'. Studies
selected as 'exclude' by both authors will be excluded from the
review. We will document the reasons for exclusion. We will resolve
any screening discrepancies through discussion or, if necessary,
through consultation with a third author. One review author (AK)
will screen the economic search results.
Living systematic review considerations
We will immediately screen any new citations retrieved by the six-
monthly searches.
Data extraction and management
For eligible studies, two review authors will extract the data using
a piloted data extraction form. We will contact the authors of the
original reports to obtain further details if the data reported are
unclear or incomplete. One review author will enter the data into
Review Manager (RevManWeb) (RevMan Web 2021), and a second
review author will verify that the data have been entered correctly.
We will extract the following study characteristics, which may act as
eCect modifiers.
• Methods: study design, number and location of study centre(s),
date of study and total duration.
• Participants: inclusion and exclusion criteria, number
randomised, number lost to follow-up or withdrawn, number
analysed, mean age and standard deviation (SD), age range,
gender.
• Interventions: description of intervention and comparator.
• Outcomes: primary and secondary outcomes specified and
collected, and time points reported. Unit of analysis.
• Notes: funding for trial and conflicts of interest of trial authors.
Assessment of risk of bias in included studies
Two review authors will independently assess the risk of bias in the
included studies for all outcomes using the revised Cochrane risk
of bias tool for randomised trials (RoB 2), described in Chapter 8
of the Cochrane Handbook for Systematic Reviews of Interventions
(hereaHer referred to as the Cochrane Handbook; Higgins 2019a).
The risk of bias tool covers five domains of bias:
• bias arising from the randomisation process;
• bias due to deviations from intended interventions;
• bias due to missing outcome data;
• bias in measurement of the outcome; and
• bias in selection of the reported result.
These domain-level judgements provide the basis for an overall risk
of bias judgement for the specific outcome being assessed. The
response options for an overall risk of bias judgement in RoB 2 are
the same as for individual domains (i.e. 'low risk of bias'; 'some
concerns'; 'high risk of bias').
If applicable, we will use the versions of RoB 2 designed for cluster-
randomised and cross-over trials.
We will assess the eCect of assignment to intervention (the
intention-to-treat eCect).
Assessment of bias in conducting the systematic review
We will conduct the review according to this published protocol and
report any deviations from it in the 'DiCerences between protocol
and review' section of the systematic review.
Measures of treatment e:ect
We will report mean diCerences (MDs) for continuous outcome
measures and risk ratios (RRs) for dichotomous outcomes. If
diCerent instruments are used to measure the same continuous
outcome, we will use the standardised mean diCerence (SMD) with
95% confidence intervals (CIs).
Unit of analysis issues
When only one eye per participant is randomised, the unit of
analysis will be the individual eye (participant). When both eyes
from the same participant are randomised (either to the same or
diCerent interventions), we will attempt to analyse data that has
been adjusted for clustering or paired-eye design. In multi-arm
trials, we will treat the multiple comparisons as being independent
in pairwise meta-analyses. In the NMA, we will account for the
correlation between the eCect sizes derived from the same study.
If we identify cluster RCTs, we will include these in meta-analyses
directly where the sample size has been adjusted for clustering. We
will consider it reasonable to combine the results from individual-
and cluster-randomised trials if there is little heterogeneity
between the study designs and the interaction between the eCect
of the intervention and the unit of randomisation is considered
to be unlikely. If outcomes are presented at individual level (i.e.
a unit of analysis error) we will use established methods to
adjust for clustering by calculating an eCective sample size by
dividing the original sample size by the design eCect which can
be calculated from the average cluster size and the intra-class
correlation coeCicient (ICC). Where the ICC is unknown, this will be
estimated from similar trials.
Interventions for myopia control in children: a living systematic review and network meta-analysis (Protocol)
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For cross-over trials, estimates that properly account for the cross-
over design will be handled in the same way as estimates from
parallel-group trials. For inappropriately reported cross-over trials,
we will attempt to approximate a paired analysis by imputing
missing standard deviations as described in Chapter 23 of the
Cochrane Handbook (Higgins 2019b).
Dealing with missing data
We will contact study authors to verify key study characteristics
and obtain missing outcome data. If we do not receive a response
within eight weeks, we will analyse the studies based on available
data. We will use the RevMan calculator to calculate missing
standard deviations using other data from the trial (e.g. confidence
intervals) based on methods outlined in Chapter 10 of the Cochrane
Handbook (Deeks 2020). We will explore the impact of including
studies with high levels of missing data in the overall assessment of
treatment eCect using sensitivity analysis.
Assessment of heterogeneity
We will assess clinical and methodological heterogeneity for
each pairwise meta-analysis by comparing the characteristics
of included studies and by visual inspection of forest plots.
We will assess statistical heterogeneity quantitatively for direct
comparisons using the Chi2 test and the I2 values. We will interpret
I2   values according to Chapter 9 of the Cochrane Handbook
(McKenzie 2019), as follows:
• 0% to 40% may not be important;
• 30% to 60% may represent moderate heterogeneity;
• 50% to 90% may represent substantial heterogeneity;
• 75% to 100% represents considerable heterogeneity.
For the NMA, we will assume a common estimate for the
heterogeneity variance across the diCerent comparisons. The
assessment of statistical heterogeneity will be based on the
magnitude of the heterogeneity variance parameter (Tau2)
estimated from the NMA models.
Assessment of statistical inconsistency
Local approaches for evaluating inconsistency
To evaluate the presence of inconsistency locally, we will use the
node splitting approach (Dias 2010), which separates evidence for
a particular comparison (node) depending on whether it comes
from studies that provide 'direct' or 'indirect' information about a
particular eCect. We will assume a common heterogeneity estimate
within each loop.
Global approaches for evaluating inconsistency
To check the assumption of consistency across the entire network,
we will use the 'design by treatment' interaction model using the
'network' command in STATA (White 2015). This method accounts
for diCerent sources of inconsistency that can occur when studies
with diCerent designs are incorporated into the network (e.g.
two-arm trials versus multi-arm trials), as well as inconsistency
between direct and indirect evidence. We will judge the presence of
inconsistency from any source in the entire network based on the
Chi2 test.
Assessment of reporting biases
We will use comparison-adjusted funnel plots to assess small study
eCect, which could be due to publication bias (Chaimani 2015).
If there are suCicient studies, we also plan to run network meta-
regression models to detect associations between study size and
eCect size.
Data synthesis
We will initially carry out standard pairwise meta-analyses to
pool outcome data using random-eCects models in RevMan Web.
For comparisons with three or fewer trials, we will use a fixed-
eCect model. We will combine change from baseline data in
meta-analyses with mean outcome data using the generic inverse
variance (unstandardised) MD method, as outlined in Chapter 10
of the Cochrane Handbook (Deeks 2020). In the case of substantial
clinical, methodological or statistical heterogeneity, we will not
attempt to combine data from individual trials but will report study
results separately.
If the included studies are suCiciently similar with respect to the
distribution of eCect modifiers, we will conduct a NMA for myopia
progression as defined by change in spherical equivalent refractive
error and axial length using random-eCects multivariate models
(Chaimani 2013; Chaimani 2015; White 2015). We will perform this
analysis using the network suite of programs available in STATA
(http://www.stata.com). We will assume a common heterogeneity
across all comparisons in the network. For all outcomes where NMA
is possible, will use the mean rank value to rank the interventions
for all available outcomes (Chaimani 2015; Salanti 2012).
In our primary analysis, each pharmacological intervention will
be considered as a node in the analysis regardless of the doses.
In a secondary analysis, we will investigate the eCect of dose
of specific pharmacological interventions by splitting them into
separate nodes. We do not anticipate a strong dose-response eCect
except for atropine. Note that atropine will be grouped according to
dosing regime as high (≥ 0.5%), moderate (0.1 % to < 0.5%) and low
(< 0.1%). For multifocal soH contact lenses, these will be grouped
into a single node for the primary analysis and then split according
to the add power (≤ +2.00 D or > +2.00 D) in a secondary analysis.
If we are unable to perform a meta-analysis, we will undertake
a narrative synthesis following guidance in Chapter 12 of
the  Cochrane Handbook (McKenzie 2020). Specifically, we will
present the eCect estimates in structured tables and provide a
descriptive summary of the range and distribution of the observed
eCects. In particular, we will note the direction of eCects and
whether these are consistent in the individual studies.
Brief economic commentary (BEC)
Following the search outlined in the Search methods for
identification of studies, we will develop a BEC to summarise
the availability and principal findings of the full economic
evaluations assessing interventions for myopia control in children
as outlined in Chapter 20 of the Cochrane Handbook (Aluko
2020). This BEC will encompass full economic evaluations (i.e.
cost-eCectiveness analyses, cost-utility analyses and cost-benefit
analyses) conducted as part of a single empirical study, such as a
RCT, a model based on a single such study or a model based on
several such studies.
Living systematic review considerations
Whenever we identify new evidence (i.e. new studies, data, or
other information) that is relevant to the review, we will extract
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the data and assess risk of bias, as appropriate. We will wait until
the accumulating evidence changes one or more of the following
components of the review before incorporating it and re-publishing
the review.
• The findings of one or more outcomes (e.g. clinically important
change in size or direction of eCect).
• Credibility (e.g. change in the confidence in one or more CINeMA
domains (Confidence In Network Meta-analysis; Salanti 2014)).
Formal sequential meta-analysis approaches will not be used for
updated meta-analyses.
Subgroup analysis and investigation of heterogeneity
We will perform subgroup analyses for types of intervention
modalities (i.e. spectacle and contact lens designs, and specific
pharmaceutical agents). If suCicient studies are available, we will
also conduct subgroup analyses according to:
• participant age (< 12 years versus > 12 years);
• ethnicity (Asian versus non-Asian);
• degree of myopia at baseline; and
• administration frequency and dose of particular pharmaceutical
interventions (e.g. low-, moderate- and high-dose atropine).
We will assess subgroup diCerences within the networks for the
primary outcome by comparing their relative treatment eCects and
their relative treatment ranking.
Sensitivity analysis
We will undertake sensitivity analyses by removal of trials that
caused high heterogeneity in direct comparisons. We will also
explore the impact of including studies at high risk of bias and with
high levels of missing data in the overall assessment of treatment
eCect.
Methods for future updates
We will review the scope and methods of this review annually in
light of potential changes in the topic area or in evidence available
for inclusion in the review. Each year, we will consider the necessity
for the review to be a living systematic review by assessing ongoing
relevance of the question to decision-makers and by determining
whether uncertainty is ongoing in the evidence and whether further
relevant research is likely.
Summary of findings and assessment of the certainty of the
evidence
We will follow methods presented in Yepes-Nunez 2019 to prepare
Summary of findings tables for the NMA.
These outcomes will be included in the Summary of findings tables:
• progression of myopia;
• change in refractive error and axial length following cessation of
treatment;
• incidence of adverse events;
• quality of life; and
• treatment adherence
Evaluating confidence in the evidence
We will use the CINeMA framework for evaluating the confidence
in the domains (Salanti 2014): within-study bias (i.e. risk of bias in
the included studies), across-studies bias (i.e. publication and other
reporting bias in the included studies), indirectness, imprecision,
heterogeneity and incoherence. CINeMA assigns judgements at
three levels (no concerns, some concerns, or major concerns)
to each of the six domains. Judgements across the six domains
are then summarised to obtain four levels of confidence for
each relative treatment eCect, corresponding to the usual GRADE
approach: very low, low, moderate, or high (Nikolakopoulou 2020).
Among the six confidence domains, the domains for within-study
bias and indirectness are based on the contribution made by each
study to each estimate of eCect on a 0% to 100% scale ('percentage
contribution matrix'). Judgement on imprecision, heterogeneity,
and incoherence relies on defining relative treatment eCects that
exclude any clinically important diCerences in outcomes between
interventions.
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Myopia] explode all trees
#2 myop*
#3 short near sight*
#4 #1 or #2 or #3
#5 (undercorrect* or slow* or progress* or control* or retard* or funct*) near/5 (myopia or myopic or myopes)
#6 (bifocal or multifocal) near/4 (myopia or myopic) near/4 (slow* or progress* or control*)
#7 prismatic bifocal*
#8 prism near/2 bifocal*
#9 base-in prism
#10 executive near/2 bifocal*
#11 progressive next addition near/3 lens*
#12 positive next lens* near/3 addition
#13 PA-PALs
#14 peripheral near/2 defocus near/4 lens*
#15 Defocus Incorporated Multiple Segments
#16 MyoVision or MyopiLux or Myosmart
#17 #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16
#18 (Concentric or gradient) near/3 lens*
#19 dual near/2 focus*
#20 extend* near/2 depth near/3 focus
#21 extend* near/2 depth near/4 field*
#22 extend* near/2 range near/3 focus
#23 extend* near/2 range near/4 field*
#24 extend* near/2 DOF
#25 EDOF
#26 #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25
#27 #5 and #26
#28 MiSight or Biofinity Multifocal or Proclear Multifocal
#29 MeSH descriptor: [Orthokeratologic Procedures] explode all trees
#30 orthokeratology or Ortho-K
#31 #28 or #29 or #30
#32 MeSH descriptor: [Atropine] explode all trees
#33 atropine*
#34 MeSH descriptor: [Cyclopentolate] explode all trees
#35 cyclopentolate*
#36 MeSH descriptor: [Pirenzepine] explode all trees
#37 pirenzepine*
#38 MeSH descriptor: [Tropicamide] explode all trees
#39 tropicamide*
#40 methylxanthine*
#41 #5 #32 or #33 or #34 or #35 #36 or #37 or #38 or #39 or #40
#42 MeSH descriptor: [Leisure Activities] explode all trees
#43 outdoor* or out door*
#44 outside or out side
#45 #42 or #43 or #44
#46 #5 or #17 or #27 or #31 or #41 or #45
#47 MeSH descriptor: [Child] explode all trees
#48 MeSH descriptor: [Adolescent] this term only
#49 MeSH descriptor: [Pediatrics] explode all trees
#50 boy* or girl* or child* or minor*
#51 adolescen* or juvenile* or teen or teens or teenage* or youth or youths or underage
#52 (primary or elementary or high or secondary) near/1 school*
#53 paediatric* or pediatric*
#54 #47 or #48 or #49 or #50 or #51 or #52 or #53
#55 #4 and #46
#56 #54 and #55
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Appendix 2. MEDLINE Ovid search strategy
1. randomized controlled trial.pt.









11. 9 not (9 and 10)
12. 8 not 11
13. exp myopia/
14. (myopia or myopic or myopes).tw.
15. ((short or near) adj3 sight$).tw.
16. or/13-15
17. ((undercorrect$ or slow$ or progress$ or control$ or retard$ or funct$) adj5 (myopia or myopic or myopes)).tw.
18. ((bifocal or multifocal) adj4 (myopia or myopic) adj4 (slow$ or progress$ or control$)).tw.
19. prismatic bifocal$.tw.
20. (near adj1 prism adj4 bifocal$).tw.
21. base-in prism.tw.
22. (executive adj2 bifocal$).tw.
23. (progressive adj1 addition adj3 lens$).tw.
24. (positive adj1 lens$ adj3 addition).tw.
25. PA-PALs.tw.
26. (peripheral adj2 defocus adj4 lens$).tw.
27. Defocus Incorporated Multiple Segments.tw.
28. (MyoVision or MyopiLux or Myosmart).tw.
29. or/18-28
30. ((Concentric or gradient) adj3 lens$).tw.
31. (dual adj2 focus$).tw.
32. (extend$ adj2 depth adj3 focus).tw.
33. (extend$ adj2 depth adj4 field$).tw.
34. (extend$ adj2 range adj3 focus).tw.
35. (extend$ adj2 range adj4 field$).tw.
36. (extend$ adj2 DOF).tw.
37. EDOF.tw.
38. or/30-37
39. 17 and 38
40. (MiSight or Biofinity Multifocal or Proclear Multifocal).tw.
41. Orthokeratologic Procedures/












54. exp Leisure Activities/
55. (outdoor$ or out door$).tw.
56. (outside or out side).tw.
57. (near adj2 work$).tw.
58. or/54-57
59. 17 or 29 or 39 or 43 or 53 or 58
60. exp Child/
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61. Adolescent/
62. exp Pediatrics/
63. (boy$ or girl$ or child$ or minor$).tw.
64. (adolescen$ or juvenile$ or teen or teens or teenage$ or youth or youths or underage).tw.
65. ((primary or elementary or high or secondary) adj1 school$).tw.
66. (schoolchild$ or schoolage or schoolboy$ orschoolgirl$ or highschool$).tw.
67. (paediatric$ or pediatric$).tw.
68. or/60-67
69. 16 and 59
70. 12 and 69
71. 68 and 70
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville 2006.
Appendix 3. MEDLINE Ovid economics search strategy
1. Economics/
2. exp "costs and cost analysis"/
3. Economics, Dental/




8. (economic$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).ti,ab.
9. (expenditure$ not energy).ti,ab.
10. value for money.ti,ab.
11. budget$.ti,ab.
12. or/1-11
13. ((energy or oxygen) adj cost).ti,ab.
14. (metabolic adj cost).ti,ab.
15. ((energy or oxygen) adj expenditure).ti,ab.
16. or/13-15





22. 17 not 21
23. exp animals/ not humans/
24. 22 not 23
25. bmj.jn.
26. "cochrane database of systematic reviews".jn.
27. health technology assessment winchester england.jn.
28. or/25-27
29. exp myopia/
30. (myopia or myopic or myopes).tw.
31. ((short or near) adj3 sight$).tw.
32. or/29-31
33. ((undercorrect$ or slow$ or progress$ or control$ or retard$ or funct$) adj5 (myopia or myopic or myopes)).tw.
34. ((bifocal or multifocal) adj4 (myopia or myopic) adj4 (slow$ or progress$ or control$)).tw.
35. prismatic bifocal$.tw.
36. (near adj1 prism adj4 bifocal$).tw.
37. base-in prism.tw.
38. (executive adj2 bifocal$).tw.
39. (progressive adj1 addition adj3 lens$).tw.
40. (positive adj1 lens$ adj3 addition).tw.
41. PA-PALs.tw.
42. (peripheral adj2 defocus adj4 lens$).tw.
43. Defocus Incorporated Multiple Segments.tw.
44. (MyoVision or MyopiLux or Myosmart).tw.
45. or/34-44
46. ((Concentric or gradient) adj3 lens$).tw.
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47. (dual adj2 focus$).tw.
48. (extend$ adj2 depth adj3 focus).tw.
49. (extend$ adj2 depth adj4 field$).tw.
50. (extend$ adj2 range adj3 focus).tw.
51. (extend$ adj2 range adj4 field$).tw.
52. (extend$ adj2 DOF).tw.
53. EDOF.tw.
54. or/46-53
55. 33 and 54
56. (MiSight or Biofinity Multifocal or Proclear Multifocal).tw.
57. Orthokeratologic Procedures/












70. exp Leisure Activities/
71. (outdoor$ or out door$).tw.
72. (outside or out side).tw.
73. (near adj2 work$).tw.
74. or/70-73
75. 33 or 45 or 55 or 59 or 69 or 74
76. 32 and 75
77. 28 and 76
Appendix 4. MEDLINE Ovid adverse events search strategy
1. (ae or co or de).fs.
2. (safe or safety or side eCect$ or undesirable eCect$ or treatment emergent or tolerability or toxicity or adrs).ti,ab.
3. (adverse adj2 (eCect or eCects or reaction or reactions or event or events or outcome or outcomes)).ti,ab.
4. or/1-3
5. exp myopia/
6. (myopia or myopic or myopes).tw.
7. ((short or near) adj3 sight$).tw.
8. or/5-7
9. ((undercorrect$ or slow$ or progress$ or control$ or retard$ or funct$) adj5 (myopia or myopic or myopes)).tw.
10. ((bifocal or multifocal) adj4 (myopia or myopic) adj4 (slow$ or progress$ or control$)).tw.
11. prismatic bifocal$.tw.
12. (near adj1 prism adj4 bifocal$).tw.
13. base-in prism.tw.
14. (executive adj2 bifocal$).tw.
15. (progressive adj1 addition adj3 lens$).tw.
16. (positive adj1 lens$ adj3 addition).tw.
17. PA-PALs.tw.
18. (peripheral adj2 defocus adj4 lens$).tw.
19. Defocus Incorporated Multiple Segments.tw.
20. (MyoVision or MyopiLux or Myosmart).tw.
21. or/10-20
22. ((Concentric or gradient) adj3 lens$).tw.
23. (dual adj2 focus$).tw.
24. (extend$ adj2 depth adj3 focus).tw.
25. (extend$ adj2 depth adj4 field$).tw.
26. (extend$ adj2 range adj3 focus).tw.
27. (extend$ adj2 range adj4 field$).tw.
28. (extend$ adj2 DOF).tw.
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29. EDOF.tw.
30. or/22-29
31. 9 and 30
32. (MiSight or Biofinity Multifocal or Proclear Multifocal).tw.
33. Orthokeratologic Procedures/












46. exp Leisure Activities/
47. (outdoor$ or out door$).tw.
48. (outside or out side).tw.
49. (near adj2 work$).tw.
50. or/46-49
51. 9 or 21 or 31 or 35 or 45 or 50
52. 8 and 51
53. 4 and 52
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Golder 2006
Appendix 5. Embase Ovid search strategy
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
12. exp clinical trial/
13. (clin$ adj3 trial$).tw.




18. exp experimental design/
19. exp crossover procedure/
20. exp control group/
21. exp latin square design/
22. or/12-21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25-28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
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33. myopia/
34. (myopia or myopic or myopes).tw.
35. ((short or near) adj3 sight$).tw.
36. or/33-35
37. ((undercorrect$ or slow$ or progress$ or control$ or retard$ or funct$) adj5 (myopia or myopic or myopes)).tw.
38. ((bifocal or multifocal) adj4 (myopia or myopic) adj4 (slow$ or progress$ or control$)).tw.
39. prismatic bifocal$.tw.
40. (near adj1 prism adj4 bifocal$).tw.
41. base-in prism.tw.
42. (executive adj2 bifocal$).tw.
43. (progressive adj1 addition adj3 lens$).tw.
44. (positive adj1 lens$ adj3 addition).tw.
45. PA-PALs.tw.
46. (peripheral adj2 defocus adj4 lens$).tw.
47. Defocus Incorporated Multiple Segments.tw.
48. (MyoVision or MyopiLux or Myosmart).tw.
49. or/38-48
50. ((Concentric or gradient) adj3 lens$).tw.
51. (dual adj2 focus$).tw.
52. (extend$ adj2 depth adj3 focus).tw.
53. (extend$ adj2 depth adj4 field$).tw.
54. (extend$ adj2 range adj3 focus).tw.
55. (extend$ adj2 range adj4 field$).tw.
56. (extend$ adj2 DOF).tw.
57. EDOF.tw.
58. or/50-57
59. 37 and 58
60. (MiSight or Biofinity Multifocal or Proclear Multifocal).tw.
61. orthokeratology lens/














76. (outdoor$ or out door$).tw.
77. (outside or out side).tw.





83. (boy$ or girl$ or child$ or minor$).tw.
84. (adolescen$ or juvenile$ or teen or teens or teenage$ or youth or youths or underage).tw.
85. ((primary or elementary or high or secondary) adj1 school$).tw.
86. (schoolchild$ or schoolage or schoolboy$ orschoolgirl$ or highschool$).tw.
87. (paediatric$ or pediatric$).tw.
88. or/80-87
89. 37 or 49 or 59 or 63 or 74 or 79
90. 36 and 89
91. 32 and 90
92. 88 and 91
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Appendix 6. Embase Ovid economics search strategy
1. Health Economics/
2. exp Economic Evaluation/
3. exp Health Care Cost/
4. pharmacoeconomics/
5. or/1-4
6. (econom$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).ti,ab.
7. (expenditure$ not energy).ti,ab.
8. (value adj2 money).ti,ab.
9. budget$.ti,ab.
10. or/6-9





16. 11 not 15
17. (metabolic adj cost).ti,ab.
18. ((energy or oxygen) adj cost).ti,ab.
19. ((energy or oxygen) adj expenditure).ti,ab.
20. or/17-19
21. 16 not 20
22. animal/
23. exp animal experiment/
24. nonhuman/





30. 26 not (26 and 29)
31. 21 not 30
32. 0959-8146.is.
33. (1469-493X or 1366-5278).is.
34. 1756-1833.en.
35. or/32-34
36. 31 not 35
37. Conference abstract.pt.
38. 36 not 37
39. myopia/
40. (myopia or myopic or myopes).tw.
41. ((short or near) adj3 sight$).tw.
42. or/39-41
43. ((undercorrect$ or slow$ or progress$ or control$ or retard$ or funct$) adj5 (myopia or myopic or myopes)).tw.
44. ((bifocal or multifocal) adj4 (myopia or myopic) adj4 (slow$ or progress$ or control$)).tw.
45. prismatic bifocal$.tw.
46. (near adj1 prism adj4 bifocal$).tw.
47. base-in prism.tw.
48. (executive adj2 bifocal$).tw.
49. (progressive adj1 addition adj3 lens$).tw.
50. (positive adj1 lens$ adj3 addition).tw.
51. PA-PALs.tw.
52. (peripheral adj2 defocus adj4 lens$).tw.
53. Defocus Incorporated Multiple Segments.tw.
54. (MyoVision or MyopiLux or Myosmart).tw.
55. or/44-54
56. ((Concentric or gradient) adj3 lens$).tw.
57. (dual adj2 focus$).tw.
58. (extend$ adj2 depth adj3 focus).tw.
59. (extend$ adj2 depth adj4 field$).tw.
60. (extend$ adj2 range adj3 focus).tw.
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61. (extend$ adj2 range adj4 field$).tw.
62. (extend$ adj2 DOF).tw.
63. EDOF.tw.
64. or/56-63
65. 43 and 64
66. (MiSight or Biofinity Multifocal or Proclear Multifocal).tw.
67. orthokeratology lens/














82. (outdoor$ or out door$).tw.
83. (outside or out side).tw.
84. (near adj2 work$).tw.
85. or/81-84
86. 43 or 55 or 65 or 69 or 80 or 85
87. 42 and 86
88. 38 and 87
Appendix 7. Embase Ovid adverse events search strategy
1. DRUG/ae
2. (safe or safety or side eCect$ or undesirable eCect$ or treatment emergent or tolerability or toxicity or adrs).ti,ab.
3. (adverse adj2 (eCect or eCects or reaction or reactions or event or events or outcome or outcomes)).ti,ab.
4. or/1-3
5. myopia/
6. (myopia or myopic or myopes).tw.
7. ((short or near) adj3 sight$).tw.
8. or/5-7
9. ((undercorrect$ or slow$ or progress$ or control$ or retard$ or funct$) adj5 (myopia or myopic or myopes)).tw.
10. ((bifocal or multifocal) adj4 (myopia or myopic) adj4 (slow$ or progress$ or control$)).tw.
11. prismatic bifocal$.tw.
12. (near adj1 prism adj4 bifocal$).tw.
13. base-in prism.tw.
14. (executive adj2 bifocal$).tw.
15. (progressive adj1 addition adj3 lens$).tw.
16. (positive adj1 lens$ adj3 addition).tw.
17. PA-PALs.tw.
18. (peripheral adj2 defocus adj4 lens$).tw.
19. Defocus Incorporated Multiple Segments.tw.
20. (MyoVision or MyopiLux or Myosmart).tw.
21. or/10-20
22. ((Concentric or gradient) adj3 lens$).tw.
23. (dual adj2 focus$).tw.
24. (extend$ adj2 depth adj3 focus).tw.
25. (extend$ adj2 depth adj4 field$).tw.
26. (extend$ adj2 range adj3 focus).tw.
27. (extend$ adj2 range adj4 field$).tw.
28. (extend$ adj2 DOF).tw.
29. EDOF.tw.
30. or/22-29
31. 9 and 30
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32. (MiSight or Biofinity Multifocal or Proclear Multifocal).tw.
33. orthokeratology lens/














48. (outdoor$ or out door$).tw.
49. (outside or out side).tw.
50. (near adj2 work$).tw.
51. or/47-50
52. 9 or 21 or 31 or 35 or 46 or 51
53. 8 and 52
54. 4 and 53
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Golder 2006.
Appendix 8. ISRCTN search strategy
myopia AND (undercorrect OR slow OR progress OR control)
Appendix 9. ClinicalTrials.gov search strategy
myopia AND (undercorrect OR slow OR progress OR control) | Interventional Studies | Child
Appendix 10. WHO ICTRP search strategy
myopia AND undercorrect OR myopia AND slow OR myopia AND progress OR myopia AND control
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